Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1094)	3/17/2003 10:55:48 PM
From: RCMac	Read Replies (1) \| Respond to of 1834

Early to worry even if there's anything to worry about here, and the market certainly didn't worry about it today, but I thought this should be linked to the NBIX thread: Message 18709608 With the current [impressive: $47.5M] round of financing, Hypnion expects to enter clinical trials with several proprietary compounds that have superior preclinical efficacy and safety compared to the current market leaders in sleep and wake promotion. . . . . . Hypnion has proprietary rights to the world's most advanced in-vivo sleep-wake testing system -- SCORE-2000(TM). Based on 15 years of research at Stanford University and developed by Hypnion's Chief Science and Technology Officer, Dr. Dale Edgar, SCORE-2000(TM) is highly predictive of human response for many sleep-wake efficacy and side-effect parameters, significantly lowering clinical trial risk. Through SCORE, Hypnion is targeting innovative medicines designed to be highly efficacious and less prone to undesirable side effects than existing drugs. The patient population for sleep disorders is larger than those for anxiety or depression and represents a potential $10 billion market in the U.S. Initially the company is transforming safe, marketed compounds into sleep-wake therapeutics by designing patentable analogs that have optimal sleep-wake efficacy and minimal side effects. These compounds work on primary sleep-wake pathways that have no evidence of addiction or abuse potential. The company has three such preclinical drug programs and many more under evaluation. Under the leadership of Dr. James White, Executive Vice President of Research and Development and Dr. Dale Edgar, Hypnion has selected a clinical development candidate for its lead insomnia program and several backup compounds. The company expects to select preclinical development candidates for two other lead programs this year.